Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167447 | 0.86 | CES2 (0.64) | THRBCES2CES1KMT2ATDP1 | |
| SCHEMBL105807 | 0.84 | THRB (1.00) | THRBCA12CA1CA2CA7 | |
| SCHEMBL31588491 | 0.80 | THRB (0.54) | THRBCES2CES1CA12CA1 | |
| SCHEMBL617480 | 0.80 | CA12 (0.70) | THRBCES2CES1CA12CA1 | |
| SCHEMBL27203878 | 0.79 | KMT2A (0.51) | THRBCES2CES1CA12CA1 | |
| SCHEMBL12160758 | 0.78 | CES2 (0.54) | THRBCES2CES1KMT2ATDP1 | |
| SCHEMBL8257722 | 0.78 | THRB (0.46) | THRBCES2CES1CA12CA1 | |
| SCHEMBL8174459 | 0.78 | CES2 (0.54) | THRBCES2CES1CA12CA1 | |
| SCHEMBL28871108 | 0.78 | CA12 (0.67) | THRBCES2CES1CA12CA1 | |
| SCHEMBL29691129 | 0.78 | THRB (0.46) | THRBCES2CES1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530786-B | Film stripping liquid suitable for flexible circuit board and preparation method thereof | 深圳市天熙科技开发有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118530786-A | Film stripping liquid suitable for flexible circuit board and preparation method thereof | 深圳市天熙科技开发有限公司 | 2024-08-23 | — | — | CN | claimed |
| US-12583856-B2 | Inhibitors of protein kinase A | BLUEPRINT MEDICINES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-12-09 | — | — | US | disclosed |
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12384801-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD. (AU) | 2025-08-12 | — | — | US | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-5399584-A | Preventing gastrointestinal damage caused by nonsteroidal antiinflammatory drugs | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1991012255-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1991-08-22 | — | — | WO | disclosed |
| EP-0224332-B1 | HETEROCYCLIC AMINO COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1990-08-08 | — | — | EP | disclosed |
| WO-1990001481-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1990-02-22 | — | — | WO | disclosed |
| EP-0354693-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1990-02-14 | — | — | EP | disclosed |
| US-4769367-A | ANTIDEPRESSANTS | GLAXO GROUP LIMITED (GB) | 1988-09-06 | — | — | US | disclosed |
| EP-0224332-A1 | Heterocyclic amino compounds | GLAXO GROUP LIMITED (GB) | 1987-06-03 | — | — | EP | disclosed |
| EP-0115142-B1 | CHROMAN COMPOUNDS | ICI AMERICAS INC. (US) | 1986-11-05 | — | — | EP | disclosed |
| EP-0115142-A1 | Chroman compounds | ICI AMERICAS INC. (US) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | THRB 2018/4885CES2 2280/4885CES1 694/4885 |
| US-12384801-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, MAVS | THRB 2142/4885CES2 3595/4885CES1 3484/4885 |
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | CHEK1, CHEK2, CCNK | THRB 2718/4885CES2 3253/4885CES1 1409/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | THRB 1210/4885CES2 1713/4885CES1 1165/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | THRB 329/4885CES2 315/4885CES1 69/4885 |
| US-12583856-B2 | Inhibitors of protein kinase A | CSNK1A1, CSNK1A1L, CSNK1G1 | THRB 493/4885CES2 1936/4885CES1 761/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | THRB 1210/4885CES2 1713/4885CES1 1165/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | THRB 2353/4885CES2 793/4885CES1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.